- Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
- Avidity Biosciences to Participate in Upcoming Investor Conference
- Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Avidity Biosciences to Participate in Upcoming Investor Conferences
- Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
- Avidity Biosciences Honors Rare Disease Day®
- Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
- Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
- Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
More ▼
Key statistics
On Friday, Avidity Biosciences Inc (RNA:NMQ) closed at 25.96, -6.15% below its 52-week high of 27.66, set on Apr 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.40 |
---|---|
High | 27.20 |
Low | 25.65 |
Bid | 24.75 |
Offer | 27.99 |
Previous close | 27.10 |
Average volume | 865.08k |
---|---|
Shares outstanding | 95.62m |
Free float | 90.16m |
P/E (TTM) | -- |
Market cap | 2.59bn USD |
EPS (TTM) | -2.95 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼